Previous Article | Next Article 
J Virol, July 1998, p. 5948-5954, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Fas Ligand-Mediated Lysis of Self Bystander Targets
by Human Papillomavirus-Specific CD8+ Cytotoxic T
Lymphocytes
Mark J.
Smyth,*
Erika
Krasovskis, and
Ricky W.
Johnstone
Cellular Cytotoxicity Laboratory, The Austin
Research Institute, Heidelberg 3084, Victoria, Australia
Received 25 February 1998/Accepted 8 April 1998
 |
ABSTRACT |
Mouse cytotoxic T lymphocytes (CTL) reactive with a
H-2Db-presented 9-mer peptide of the human papillomavirus
type 16 protein E749-57 (RAHYNIVTF) were generated from the
spleen cells of wild-type C57BL/6 (B6) or B6 perforin-deficient
(B6.P0) mice. CD8+ B6 CTL displayed
peptide-specific perforin- and Fas-mediated lysis of E7-transfected
mouse RMA lymphoma cells (RMA-E7), while CD8+ CTL from
B6.P0 mice lysed RMA-E7 cells via Fas ligand (FasL)
exclusively. Rapid and efficient lysis of syngeneic bystander B6 blasts
or RMA cells by either B6 or B6.P0 Ag-activated CTL was
mediated by a FasL-Fas mechanism. Fas-resistant bystanders were not
lysed, nor were allogeneic Fas-sensitive C3H/HeJ (H-2k) or BALB/c (H-2d)
bystander blasts. Interestingly, however, phorbol myristate acetate-ionomycin preactivation of B6.P0 effectors enabled
lysis of allogeneic H-2k and
H-2d bystanders even in the absence of
antigenic stimulation. Lysis of syngeneic bystander cells was always
FasL-Fas dependent and required effector-bystander contact and, in
particular, an interaction between CTL LFA-1 and bystander ICAM-1.
Thus, in the context of major histocompatibility complex class I
molecule-peptide ligation of the T-cell receptors of CD8+
CTL, neighboring bystander cells that are syngeneic and Fas sensitive and express the adhesion molecule ICAM-1 are potential targets of CTL
attack.
 |
INTRODUCTION |
With the dissection of two basic
cytolytic mechanisms of cytotoxic T lymphocytes (CTL) (10, 14, 20,
34), it has become possible to delineate the important criteria
that determine direct (Ag-restricted) and bystander cytotoxicity. CTL
use complementary cytotoxic mechanisms, one based on the granule
exocytosis of a calcium-dependent pore-forming protein, perforin
(8, 26), and granzymes (35) and another that
depends on a calcium-independent interaction of effector T-cell tumor
necrosis factor or Fas ligand (TNF or FasL) and target cell TNF
receptor (TNFR) or Fas (22, 33). The function of the granule
exocytosis pathway appears to be largely in non-major
histocompatibility complex (MHC)-restricted NK lysis of class I
molecule-defective tumor cells and in direct CTL-mediated immunity
against tumor cells (37) or virus-infected cells (11,
19, 39). By contrast, the FasL-Fas and TNF-TNFR interactions are
important for the maintenance of T-cell homeostasis following exposure
to foreign Ag (5, 42) and Th-1 FasL-mediated B-cell
apoptosis (27, 28). Blockage of both TNF and FasL is required to abrogate T-cell death: TNF mediates the death of most CD8+ T cells, whereas FasL mediates the death of most
CD4+ T cells (42). While FasL-dependent lysis
appears to be the primary mechanism used by CD4+ Th-1
effectors, CD8+ CTL use FasL or TNF secondarily in the
absence of perforin-mediated lysis (10, 14, 20).
After T-cell activation, a functional role for FasL is not apparent for
several days until the T cell becomes Fas sensitive and hence
susceptible to autocrine T-cell suicide (1, 5, 38). However,
by using alloreactive CTL cultures or clones, it has recently become
apparent that in the presence of Ag-bearing target cells (i.e., upon
T-cell receptor [TCR] activation) CTL can also lyse Ag-free bystander
cells via a FasL-Fas interaction (13, 34). While the
specificity of CTL toward Ag-bearing target cells has been considered a
hallmark of an efficient immune response, CTL do not appear to spare
Ag-free bystander cells during lysis of specific Ag-bearing target
cells. In this study, we have generated CD8+ CTL from both
wild-type and perforin-deficient (P0) mice reactive with a
high-affinity H-2Db-binding peptide of human papillomavirus
type 16 protein E7. These peptide-specific CTL have been employed to
demonstrate the requirements for CD8+ CTL-mediated lysis of
Ag-free bystander cells and in particular the different properties of
CTL activated by antigen versus a nonspecific stimulus.
 |
MATERIALS AND METHODS |
Mice.
C57BL/6.P0 (B6.P0) mice
derived as described previously (11) were obtained from Gary
Kupariah, John Curtin School of Medical Research, Canberra, Australia.
C57BL/6 ICAM-1-deficient (B6.ICAM0) mice (32)
were obtained from The Jackson Laboratories, Bar Harbor, Maine. These
strains and B6
2µ-deficient (B6.
2µ0) mice were
maintained and bred at the Austin Research Institute Biological
Research Laboratories. C3H/HeJ, BALB/c, and B6 mice were purchased from
The Walter and Eliza Hall Institute of Medical Research, Melbourne,
Australia.
Cells and reagents.
The mouse EL4
(H-2b) thymoma, RMA
(H-2b) lymphoma, and RMA-S
(H-2b) mutant lymphoma (derived from the Raucher
virus-induced murine cell line RBL-5 and defective for peptide loading
of MHC class I molecules) (18) cell lines and an
E7-transfected clone of RMA, RMA-E7 (43), were grown in RPMI
medium supplemented with 10% (vol/vol) fetal calf serum (FCS), 2 mM
glutamine, 100 U of penicillin/ml, and 100 µg of streptomycin (Gibco,
Grand Island, N.Y.)/ml. d12S, the 12th serial subcloning of the
rat × mouse hybridoma PC60 cell line (3), was grown in
Dulbecco's modified Eagle's medium (Gibco) supplemented with 5% FCS
and additives as described above. Phorbol myristate acetate (PMA)
(Sigma Chemical Co., St. Louis, Mo.) and ionomycin (ION) (Calbiochem
Corp., San Diego, Calif.) were purchased. Soluble recombinant human
FasL (srFasL) (produced in COS cell supernatants and used neat), mouse Fas-Fc, and human p80 TNFR-Fc fusion proteins were a kind gift from
David Lynch, Immunex Corp., Seattle, Wash. Recombinant human interleukin-2 (IL-2) was a kind gift from Chiron Corp., Emeryville, Calif. Peptides of human papillomavirus type 16 protein
E749-57 (RAHYNIVTF) and chicken OVA257-264
(SIINFEKL) were synthesized (>98% pure) on an Applied Biosystems model 430A automated peptide synthesizer (12). d12S cells
were incubated for 3 h before the cytotoxicity tests with a
mixture of PMA (5 ng/ml) and ION (1 µg/ml). Spleen cells were
harvested from B6, B6.ICAM0, C3H/HeJ
(H-2k), and BALB/c (H-2d)
mice and cultured in RPMI medium supplemented with the additives described above and ION (1 µg/ml) and PMA (5 ng/ml) for 3 days. Spleen blasts were then washed three times in medium prior to their use
as target cells. Spleen blasts were >98% CD3+ as
determined by flow cytometry.
Peptide immunization and induction of B6 and B6.P0
anti-E749-57 CTL.
One hundred micrograms (100 µl of
1 mg/ml peptide solution) of peptide was extensively mixed with 100 µl of immunofluorescent antibody and 0.5% bovine serum albumin. The
200-µl mixture was injected subcutaneously into B6 or
B6.P0 mice, and the procedure was repeated after 2 weeks.
Two weeks after the second immunization the mice were sacrificed and
spleen cells were cultured overnight on plastic flasks to remove
adherent cells. Responder cells were then treated with anti-CD4
(H129.19; rat immunoglobulin G2a [IgG2a]) (Sigma) and complement
(1/30 dilution of normal rabbit serum) as previously described
(36). Stimulator RMA-S cells were cultured at 25°C for
24 h and incubated with 100 µM E749-57 peptide for 2 to 4 h at 33°C. Stimulator cells (106) were
extensively washed, irradiated (20,000 rad), and then cultured (25-cm2 culture flasks) with responder cells (2 × 107) in RPMI supplemented with 10% FCS and 5 µM peptide.
After 5 days, responder lymphocytes were harvested and cultured in
24-well plates at a density of 106 cells per well in the
same medium supplemented with 5 U of IL-2/ml. Each well received
106 irradiated RMA-E7 cells as stimulator cells. Responder
cells were restimulated weekly under the same conditions; they were >90% CD8+ as determined by immunofluorescence assay, and
their CTL activity was determined in a 4-h 51Cr release
assay with RMA-E7 target cells.
51Cr release assays.
The cytotoxicity of
responding B6 anti-E749-57 or B6.P0
anti-E749-57 CTL, d12S cells, or srFasL was assessed by
51Cr release assays for 4 h as described previously
(30). Briefly, Ag-bearing target cells (including
temperature-induced RMA-S cells that were pulse labeled with immunizing
or control peptide, as described above) or Ag-free bystander cells were
labeled with 50 µCi of 51Cr for 1 h at 37°C and
then washed three times. 51Cr-labeled Ag-bearing target
cells (104) and unlabeled bystander cells (104)
were incubated with different numbers of CTL as indicated, according to
the effector/target cell ratio. In other wells,
51Cr-labeled Ag-free cells and unlabeled Ag-bearing target
cells (also at a 1:1 ratio) were added to CTL. The spontaneous release of 51Cr was determined by incubating the target cells with
medium alone, whereas the maximum release was determined by adding
sodium dodecyl sulfate to a final concentration of 5%. The percent
specific lysis was calculated as follows: 100 × [(experimental
release
spontaneous release)/(maximum release
spontaneous release)]. In some experiments, B6 or B6.P0
anti-E749-57 CTL were incubated for 3 h before the
cytotoxicity tests with a mixture of PMA (5 ng/ml) and ION (1 µg/ml).
These cells were washed three times prior to the assay. In other
experiments, B6 or B6.P0 CTL were depleted with monoclonal
antibody (MAb) (10 µg/ml; anti-CD8 [1803; rat IgG2a] or control
anti-CD4 and complement [1/30 dilution of normal rabbit serum]) prior
to the examination of cytolysis against RMA-E7 and bystander syngeneic
target cells. Cytotoxicity tests were sometimes performed either in the
absence or presence of Fas-Fc or TNFR-Fc (at a final concentration of 5 µg/ml) and/or EGTA (Sigma) (at a final concentration of 2.5 mM). In
other tests MAb (anti-LFA-1-
[M17/4; rat IgG2a] [Pharmingen, San
Diego, Calif.], anti-CD8 [53-6.7; rat IgG2a] [Sigma], or anti-Thy
1.1 [OX-7; mouse IgG1]) was added at a final
concentration of 20 µg/ml prior to, or 1 h after, the
commencement of the cytotoxicity assay.
 |
RESULTS AND DISCUSSION |
Generation of E749-57-specific B6 and B6.P0
CD8+ CTL.
Following immunization of B6 and
B6.P0 mice with E749-57 peptide, harvested
spleen cells were depleted of CD4+ T cells and responding
CTL were expanded by several rounds of stimulation with irradiated
RMA-E7 cells. Resultant B6 and B6.P0 CTL cultures were
assayed for specific cytolytic activity towards RMA-E7 or RMA-S cells
pulsed with the E749-57 (RAHYNIVTF) peptide in a 4-h
51Cr release assay (Fig. 1).
RMA-S cells have a defect affecting peptide loading of MHC class I
molecules, and as a consequence, the cell surface expression of these
molecules is low but increases when Kb- or
Db-binding peptides are added to the culture medium
(18). Both B6 and B6.P0 CTL cultures effectively
lysed RMA-E7 or RMA-S cells pulsed with E749-57 but not
RMA-S cells pulsed with OVA257-264 or RMA-S cells alone.
From several independent immunizations and in vitro cultures,
peptide-specific lysis by B6 CTL was consistently greater than that by
B6.P0 CTL. Pretreatment of these cultures with anti-CD8 MAb
and complement, but not with control anti-CD4 MAb and complement,
completely abrogated B6 anti-E749-57 or B6.P0
anti-E749-57 CTL lysis of RMA-E7 (Fig. 1). Overall, these
data indicate that the cytotoxic effects studied were mediated by
CD8+ CTL and were specific for E749-57 peptide.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Generation of E749-57-specific B6 and
B6.P0 CD8+ CTL. Mice were immunized with
E749-57 peptide, and responding CTL were induced as
described in Materials and Methods. The resultant B6 (A) and
B6.P0 (B) CTL cultures were assayed for specific cytolytic
activity toward RMA-E7 cells, RMA-S cells alone, or RMA-S cells pulsed
with the E749-57 peptide or the OVA257-264
peptide in a 4-h 51Cr release assay. Some effectors were
pretreated with anti-CD8 MAb and complement or anti-CD4 MAb and
complement prior to examination of the cytolysis of RMA-E7 target
cells. Direct cytotoxicity was assessed at the four effector/target
ratios illustrated (104 target cells/well). Cytotoxicity
was expressed as specific 51Cr release after subtraction of
spontaneous 51Cr release, which was less than 15%. These
results were calculated as the means ± standard errors of
duplicate samples and are representative of three experiments
performed.
|
|
B6 and B6.P0 CD8+ CTL specific for
E749-57 mediate bystander lysis.
Figure
2 demonstrates that
E749-57-specific CTL from B6 or B6.P0 mice
could efficiently lyse Ag-free noncognate targets when the latter were
bystanders to lysis of Ag-bearing RMA-E7 target cells. In particular,
syngeneic (H-2b) B6 blasts and, to a lesser
extent, RMA cells acted as susceptible bystanders, while syngeneic
(H-2b) EL4 cells did not (Fig. 2A). These data
correlated with the relative Fas sensitivity of these bystander cells
(B6 blasts were more sensitive to FasL than RMA cells, and EL4 cells
were insensitive [see Fig. 5]). The levels of bystander lysis
mediated by B6 and B6.P0 CTL specific for
E749-57 were approximately equivalent. B6
anti-E749-57 or B6.P0 anti-E749-57
CTL lysed RMA-E7 cells irrespective of the type of bystander cell
present (Fig. 2B).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
B6 and B6.P0 CD8+ CTL specific
for E749-57 mediate bystander lysis. (A) Bystander lysis by
B6 (solid symbols) and B6.P0 (open symbols)
CD8+ CTL specific for E749-57 was examined at
the four effector/target ratios illustrated (104
51Cr-labeled bystanders and 104 cold RMA-E7
cells/well) against 51Cr-B6 blasts and RMA-E7 cells
(squares), 51Cr-EL4 and RMA-E7 cells (circles), or
51Cr-RMA and RMA-E7 cells (triangles) in a 4-h
51Cr release assay. Bystander lysis of B6 blasts or EL4
cells was not observed in the absence of RMA-E7 cells or presence of
RMA cells (<10% lysis at all effector/target ratios). (B) Direct
lysis by B6 (solid symbols) and B6.P0 (open symbols)
CD8+ CTL specific for E749-57 was examined at
the four effector/target ratios illustrated (104
51Cr-labeled RMA-E7 target cells and 104 cold
bystanders/well) against 51Cr-RMA-E7 cells and B6 blasts
(squares), 51Cr-RMA-E7 and EL4 cells (circles), or
51Cr-RMA-E7 and RMA cells (triangles) in a 4-h
51Cr release assay. Cytotoxicity was expressed as specific
51Cr release after subtraction of spontaneous
51Cr release, which was <15%. These results were
calculated as the means ± standard errors of duplicate samples
and are representative of two experiments performed.
|
|
Bystander lysis by E749-57-specific B6 or
B6.P0 CD8+ CTL is FasL mediated.
The
cytolytic mechanisms employed by B6 and B6.P0
CD8+ CTL specific for E749-57 were determined
by the addition of an inhibitory Fas-Fc fusion protein and/or the
Ca2+ chelator, EGTA (to block granule-mediated lysis).
Direct lysis of RMA-E7 target cells by B6 CTL specific for
E749-57 was not inhibited by Fas-Fc, was significantly
inhibited by EGTA, but was completely inhibited by a combination of
Fas-Fc and EGTA (Fig. 3A). B6 CTL
inhibited from lysing RMA-E7 targets (by the addition of EGTA) still
efficiently killed bystander B6 blasts. Thus, B6 CTL specific for
E749-57 lysed RMA-E7 target cells preferentially via
granule exocytosis, but in the absence of granule exocytosis by FasL.
By contrast, Fas-Fc alone completely blocked B6.P0
anti-E749-57-mediated lysis of RMA-E7, and EGTA was without
effect (Fig. 3B), suggesting that these P0 CTL mediated
Ag-specific lysis via FasL. A potential nonspecific inhibition of lysis
by the Fas-Fc fusion protein was unlikely given that a control TNFR-Fc
fusion protein at the same concentration was ineffective. Bystander
lysis of B6 blasts in the presence of RMA-E7, mediated by either B6
(Fig. 3C) or B6.P0 (Fig. 3D) CTL specific for
E749-57, was inhibited by Fas-Fc alone but not by TNFR-Fc
or EGTA.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3.
Bystander lysis by E749-57-specific B6 or
B6.P0 CD8+ CTL is FasL mediated. Direct lysis
by B6 (A) and B6.P0 (B) CTL specific for
E749-57 (at the four effector/target ratios illustrated;
104 51Cr-labeled RMA-E7 target cells and 104
cold B6 blasts/well) and bystander lysis by B6 (C) and
B6.P0 (D) CTL specific for E749-57 (at the four
effector/target ratios illustrated; 104 51Cr-labeled B6
blasts and 104 cold RMA-E7 cells/well) were examined in a
4-h 51Cr release assay. These assays were performed in the
absence (solid squares) or presence of Fas-Fc (open circles), EGTA
(solid circles), Fas-Fc and EGTA (solid triangles), or TNFR-Fc (open
squares). Cytotoxicity was expressed as specific 51Cr
release after subtraction of spontaneous 51Cr release,
which was <15%. These results were calculated as the means ± standard errors of duplicate samples and are representative of two
experiments performed.
|
|
Mode of CTL activation determines quantity of bystander lysis.
A previous report by Kojima et al. highlighted the fact that maximal
bystander lysis was mediated by CTL clones that were stimulated by PMA
and ION, thus bypassing TCR stimulation (13). In this
scenario, interactions between activated CTL and bystanders could be
observed in the absence of third-party, Ag-bearing stimulator cells.
These experiments were also of particular interest, since PMA-ION-stimulated CTL of H-2d origin lysed
H-2b bystander cells. By contrast, we had
previously examined bystander lysis only of syngeneic
(H-2b) cells by alloreactive CTL (b anti-k) in
the presence of H-2k target cells
(34). To further investigate bystander lysis following CTL
activation, we stimulated B6.P0 anti-E749-57
CTL with PMA-ION and/or Ag-bearing RMA-E7 cells and evaluated the
ability of these CTL to lyse bystander blasts of
H-2b, H-2k, and
H-2d origin (Fig. 4A to
D). B6.P0
anti-E749-57 CTL that were activated with RMA-E7 cells
lysed labeled syngeneic bystander B6 blasts but did not significantly
lyse H-2k C3H/HeJ blasts,
H-2d BALB/c blasts, B6.
2µ0
blasts, or FasL-insensitive EL4 cells (Fig. 4A). None of these bystander cells were lysed by B6.P0
anti-E749-57 CTL in the absence of RMA-E7 cells (Fig. 4C).
By contrast, PMA-ION activation of B6.P0
anti-E749-57 CTL stimulated equivalent lysis of all blasts
of the three H-2 haplotypes, but not EL4, in the absence of
RMA-E7 stimulator cells (Fig. 4D). Only bystander lysis of B6 blasts
was greater if RMA-E7 stimulator cells were included in the assay (Fig.
4B). This PMA-ION-activated bystander lysis was also completely
inhibited by Fas-Fc fusion protein (data not shown). Importantly,
blasts from B6, B6.
2µ0, BALB/c, and C3H/HeJ mice were
equally sensitive to srFasL, suggesting that Fas sensitivity did not
explain differential susceptibility to B6.P0
anti-E749-57 CTL-mediated bystander lysis (Fig. 4E). It
should be noted that preliminary data (not shown) also suggest that
alloreactive mouse CTL (b anti-k) do not effectively lyse
H-2d BALB/c blasts acting as bystanders. Further
experiments with B6 anti-E749-57 CTL were performed, and
their mode of bystander lysis was identical to that of
B6.P0 anti-E749-57 CTL. In particular,
perforin-mediated bystander lysis of allogeneic blasts was not
observed, even after pretreatment of B6 anti-E749-57 CTL
with PMA-ION (data not shown).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 4.
Mode of CTL activation determines type and level of
bystander lysis. Blasts of B6 (H-2b),
B6. 2µ0 (H-2b), C3H/HeJ
(H-2k), or BALB/c (H-2d)
origin or EL4 cells (H-2b) were 51Cr
labeled and used as targets for B6.P0
anti-E749-57 CTL added to Ag-bearing RMA-E7 cells (1:1
ratio) (A), B6.P0 anti-E749-57 CTL
prestimulated with PMA-ION (for 3 h) and then added to RMA-E7
cells (1:1 ratio) (B), B6.P0 anti-E749-57 CTL
alone (C), and B6.P0 anti-E749-57 CTL
prestimulated with PMA-ION for 3 h (D). Lysis by B6.P0
anti-E749-57 CTL was examined in a 4-h 51Cr
release assay at the four effector/target ratios illustrated. (E) Lysis
of blasts and EL4 target cells by doubling dilutions of srFasL.
Cytolysis was expressed as specific 51Cr release after
subtraction of spontaneous 51Cr release, which was <15%.
These results were calculated as the means ± standard errors of
duplicate samples and are representative of two experiments
performed.
|
|
Bystander lysis by E749-57-specific CTL is not via
srFasL.
We considered the possibility that differences in TCR
versus PMA-ION stimulation of B6.P0
anti-E749-57 CTL might be due to bystander killing by
soluble FasL (sFasL). CTL supernatants were collected after incubation
of B6 anti-E749-57 or B6.P0
anti-E749-57 CTL with either RMA-E7 cells or PMA-ION for
3 h. These supernatants were used as media for incubation with
51Cr-labeled syngeneic target cells (Fas sensitive or
insensitive). Figure 5 shows that no
supernatant had lytic activity toward Fas-sensitive B6 blasts or RMA
cells, while sFasL significantly lysed B6 blasts and RMA cells but not
EL4 cells. These data indicate that there is no evidence that srFasL is
responsible for effects of CTL on bystanders irrespective of the CTL
stimulus.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 5.
No FasL-mediated activity in culture supernatants from
activated CTL. Anti-E749-57 CTL from B6 and
B6.P0 mice (effectors) were stimulated with PMA-ION or
incubated with Ag-bearing RMA-E7 cells (stimulators) as for a 4-h assay
(effector/target ratio of 50:1). Supernatants were collected at 4 h and evaluated for their ability to lyse 51Cr-labeled B6
blasts, RMA cells (Fas sensitive), or EL4 cells (Fas insensitive) in a
4-h 51Cr release assay. srFasL (sFasL) was used as a
positive control. Cytolysis was expressed as specific 51Cr
release after subtraction of spontaneous 51Cr release,
which was <15%. These results were calculated as the means ± standard errors of duplicate samples.
|
|
CTL LFA-1-bystander ICAM-1 interaction is critical for bystander
lysis.
The contact dependence of bystander lysis was investigated
with MAbs to surface proteins on the B6.P0
anti-E749-57 CTL. Previous reports have highlighted the
importance of an LFA-1-ICAM-1 interaction for Th-1-mediated B-cell
apoptosis (40). MAbs were present throughout the assay or
were added after 1 h of preactivation of the CTL with RMA-E7
stimulator cells. As previously demonstrated for many forms of
Ag-specific lysis (15, 16), the anti-LFA-1 MAb or the
anti-CD8 MAb completely inhibited RMA-E7 cell lysis when present
throughout an effector-target cell assay (data not shown). By contrast,
after 1 h of incubation between B6.P0
anti-E749-57 CTL and 51Cr-labeled RMA-E7 cells,
the addition of anti-LFA-1, anti-CD8, or negative control anti-Thy 1.1 MAb did not block E749-57-specific lysis (Fig.
6A). These data suggested that the
important interactions involving the TCR-CD8 of CTL and class I
molecules-peptide of the RMA-E7 target cells were required for
activation of CTL-mediated lysis. Not surprisingly therefore, when
present throughout the assay, the anti-LFA-1 and anti-CD8 MAbs could
block B6.P0 anti-E749-57 CTL-RMA-E7
interactions, required for TCR-induced FasL expression on CTL, and thus
subsequent bystander lysis of labeled B6 blasts in an
effector-target-bystander assay (Fig. 6B). However, the simultaneous
addition of 51Cr-labeled bystander B6 blasts and MAb to CTL
preactivated by RMA-E7 cells 1 h before the assay made it possible
to determine the requirements for the delivery of a lethal hit to
bystanders by activated B6.P0 anti-E749-57 CTL
(Fig. 6C). Anti-LFA-1 MAb completely blocked the lysis of bystander B6
blasts when added 1 h after CTL activation (Fig. 6C). The ability
of anti-CD8 MAb to inhibit bystander lysis was considerably diminished
when it was added 1 h after the exposure of CTL to RMA-E7 cells
(Fig. 6C).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 6.
CTL LFA-1-bystander ICAM-1 interaction is critical for
bystander lysis. (A) Direct lysis. B6.P0
anti-E749-57 CTL and 51Cr-labeled RMA-E7 target
cells were coincubated for 4 h (open square). In some tests MAb
(anti-LFA-1 [20 µg/ml; open circles], anti-CD8 [20 µg/ml; solid
circles], or anti-Thy 1.1 [20 µg/ml; solid triangles]) was added
1 h after the coincubation commenced. (B) Bystander lysis.
B6.P0 anti-E749-57 CTL and
51Cr-labeled B6 bystanders were incubated alone (open
squares) or together with RMA-E7 target cells in the absence (solid
squares) or presence of MAb (symbols as in panel A) for 4 h. (C)
Bystander lysis. B6.P0 anti-E749-57 CTL and
RMA-E7 stimulator cells were coincubated for 1 h prior to the
addition of 51Cr-labeled B6 blasts and MAbs as in panels A
and B for a further 4 h. (D) B6.P0
anti-E749-57 CTL and RMA-E7 stimulator cells (squares) or
d12S effector cells (circles) were incubated for 4 h with
51Cr-labeled B6 blasts (solid symbols) or
B6.ICAM-10 blasts (open symbols). Lysis was determined at
the four effector/target ratios illustrated, as described in the
legends to Fig. 1 and 2, and results were calculated as the means ± standard errors of duplicate samples.
|
|
Lysis of bystander B6 blasts by PMA-ION-preactivated B6.P
0
anti-E7
49-57 CTL was also completely inhibited by
anti-LFA-1 MAb but not by
anti-CD8 MAb, further confirming a role for
LFA-1 in interactions
between activated B6.P
0
anti-E7
49-57 CTL and bystander B6 blasts (data not shown).
Pretreatment of
PMA-ION-preactivated B6.P
0
anti-E7
49-57 CTL with anti-LFA-1 MAb resulted in a complete
inhibition of
bystander lysis, while pretreatment of bystanders with
anti-LFA-1
MAb had no effect (data not shown). Thus, the inhibitory
effects
of anti-LFA-1 MAb on bystander lysis were not due to the
inhibition
of CTL-RMA-E7 cell interactions, required for CTL FasL
upregulation
(
38) or LFA-1 activation (
7,
21).
Only preactivated CTL,
as opposed to resting CTL, used their surface
LFA-1 molecules
to facilitate the effective formation of CTL-bystander
conjugates,
and after activation, CTL no longer required the signals
from
Ag-bearing target cells to kill bystander cells. Importantly,
experiments with the anti-CD8 MAb demonstrate that the
CD8-TCR-dependent
activation of CTL is critical for bystander lysis.
These data
may indicate important changes in the affinity of CTL
surface
LFA-1 (
7,
21) that enabled conjugation with Ag-free
bystander
cells. Thus, while the expression of FasL and LFA-1 on
TCR-activated
CTL was necessary, neither alone was sufficient for
bystander
lysis.
Confirmation that bystander cell ICAM-1 was interacting with CTL LFA-1
was obtained by using
51Cr-labeled blasts from
B6.ICAM-1
0 mice (Fig.
6D). ICAM-1-deficient B6 blasts were
not susceptible
bystanders, while control ICAM-1-expressing B6 blasts
were efficiently
lysed by B6.P
0 anti-E7
49-57
CTL. Importantly, B6 and B6.ICAM-1
0 blasts were equally
susceptible to d12S effector cells that kill
in a non-MHC-restricted
FasL-dependent manner (Fig.
6D). Furthermore,
ICAM-1 expression on B6
blasts but not on B6.ICAM
0 blasts was confirmed by flow
cytometry (data not shown). These
results and the data shown in Fig.
6A
to C strongly support a
critical interaction between activated CTL
LFA-1 and bystander
ICAM-1. This critical interaction between CTL LFA-1
and bystander
ICAM-1 was also observed for B6 anti-E7
49-57
CTL (data not shown).
Conclusions.
This efficient and rapid lysis of Fas-sensitive
bystanders by E749-57 peptide-specific CD8+ CTL
extends previously published observations of bystander lysis (2,
6, 13, 34, 41). However, the issue of the variable sensitivity of
bystander cells to activated Ag-specific CTL remains somewhat
unresolved. In our experimental system we have demonstrated that
Ag-specific CTL will lyse syngeneic bystander cells preferentially to
third-party allogeneic bystander cells, providing the stimulus is TCR
mediated and the bystander expresses class I molecules. If PMA-ION is
used to activate Ag-specific CTL they will lyse Fas-sensitive
bystanders irrespective of MHC class I molecule expression. Our
findings are consistent with an earlier study by Duke that defined
self-recognition of bystander target cells by using allospecific CTL
(6). However, in contrast, Kojima et al. (13)
have shown that allospecific CTL of H-2b origin
and specific for H-2k can lyse L1210-Fas
bystander cells (H-2d). The discrepancy between
the data of Kojima et al. and ours is not simply explained by CTL
activation, since these allospecific CTL were not apparently stimulated
with PMA-ION (13). Nor is it explained by the lack of ICAM-1
expression on our blast populations, as spleen blasts from B6, BALB/c,
and C3H/HeJ mice all expressed similar levels of ICAM-1 (data not
shown). The ability of CTL to lyse bystander cells is dependent on
important cell-cell interactions and the signals these interactions
mediate, and thus the most important interactions between activated CTL
and bystander cells of different lineages and activation states may
need to be defined to resolve these differences.
In the future, activation of Ag-specific CTL and/or T-cell bystander
cells by other T-cell stimuli, such as lectins (e.g.,
con A), anti-CD2
or anti-CD3 cross-linking, cytokines (e.g., IL-2),
or superantigens,
will be of interest. Maintenance of clonotype
specificity in
Fas-mediated apoptosis of mature T cells has been
hypothesized to
result from important TCR sensitization signals
at the time of Fas
engagement (
9). In these studies, neither
resting nor con
A-stimulated T-cell blasts acted as bystanders
to Ag-induced T-cell
death, suggesting that the sensitization
event necessary for bystander
T-cell death was very specific.
By contrast, in our assays, it appeared
that the sensitization
was provided to bystander T cells after
prestimulation with PMA-ION.
Arguably, such a powerful stimulus to
bystander T cells is not
physiologically relevant, but if it is, then
these data raise
the possibility that T cells of different clonotypes
may be destroyed
in vigorous or chronic Ag-specific CTL responses. In
particular,
cytokines such as IL-2 and gamma interferon are important
in predisposing
T cells to TCR-induced death (
4,
17) or
creating an environment
favorable for Fas-mediated apoptosis (
2,
4,
17,
23,
25). Thus, these cytokines may play an important
general role
in regulating bystander lysis and, consequently, immune
responses
and the resolution of disease or tumor burden.
The role that CTL-mediated bystander lysis plays in outcomes following
virus infection remains to be determined; however,
it is becoming
evident that many viruses initially enhance the
susceptibility of newly
infected cells to Fas-mediated apoptosis
(
31), and thus
CTL-mediated bystander lysis of Ag-free infected
cells might play an
important protective role in this regard.
Alternatively, bystander
lysis could play a potentially damaging
role in chronic infections that
involve tissues that can express
high levels of Fas (e.g., liver and
heart tissues) (
2,
24,
29). It is now of paramount
importance that bystander lysis
be demonstrated convincingly in vivo.
In this light, murine models
of viral infection or tumor rejection that
assess the role of
CTL FasL in direct versus bystander cytotoxicity
must be developed.
 |
ACKNOWLEDGMENTS |
We thank Bruce Loveland for critically reviewing the manuscript.
We also thank David Lynch for providing Fas-Fc, TNFR-Fc, and srFasL.
M.J.S. is currently supported by a Wellcome Trust Australasian Senior
Research Fellowship and by a Project Grant from the National Health and
Medical Research Council of Australia (NH&MRC). R.W.J. is supported by
a NH&MRC C. J. Martin Fellowship.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Cellular
Cytotoxicity Laboratory, The Austin Research Institute, Studley Rd.,
Heidelberg 3084, Victoria, Australia. Phone: 61-3-9287-0655. Fax:
61-3-9287-0600. E-mail:
m.smyth{at}ari.unimelb.edu.au.
 |
REFERENCES |
| 1.
|
Alderson, M. R.,
T. W. Tough,
T. Davis-Smith,
S. Braddy,
B. Falk,
K. A. Schooley,
R. G. Goodwin,
C. A. Smith,
F. Ramsdell, and D. H. Lynch.
1995.
Fas ligand mediates activation-induced death in human T lymphocytes.
J. Exp. Med.
181:71-77[Abstract/Free Full Text].
|
| 2.
|
Ando, K.,
K. Hiroishi,
T. Kaneko,
T. Moriyama,
Y. Muto,
N. Kayagaki,
H. Yagita,
K. Okumura, and M. Imawari.
1997.
Perforin, Fas/Fas ligand, and TNF- pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL.
J. Immunol.
158:5283-5291[Abstract].
|
| 3.
|
Conzelmann, A.,
P. Corthesy,
M. Cianfriglia,
A. Silva, and M. Nabholz.
1982.
Hybrids between rat lymphoma and mouse T cells with inducible cytolytic activity.
Nature
298:170-172[Medline].
|
| 4.
|
Critchfield, J. M.,
M. K. Racke,
J. C. Zuniga-Pflucker,
B. Cannella,
C. S. Raine,
J. Goverman, and M. J. Lenardo.
1994.
T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis.
Science
263:1139-1143[Abstract/Free Full Text].
|
| 5.
|
Dhein, J.,
H. Walczak,
C. Baumler,
K.-M. Debatin, and P. H. Krammer.
1995.
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95).
Nature
373:438-441[Medline].
|
| 6.
|
Duke, R. C.
1989.
Self-recognition by T cells. Bystander killing of target cells bearing syngeneic MHC antigens.
J. Exp. Med.
170:59-71[Abstract/Free Full Text].
|
| 7.
|
Dustin, M. L., and T. A. Springer.
1991.
Role of lymphocyte adhesion receptors in transient interactions and cell locomotion.
Annu. Rev. Immunol.
9:27-66[Medline].
|
| 8.
|
Henkart, P. A.
1985.
Mechanism of lymphocyte-mediated cytotoxicity.
Annu. Rev. Immunol.
3:31-58[Medline].
|
| 9.
|
Hornung, F.,
L. Zheng, and M. J. Lenardo.
1997.
Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes.
J. Immunol.
159:3816-3822[Abstract].
|
| 10.
|
Kagi, D.,
F. Vignaux,
B. Ledermann,
K. Burki,
V. Depraetere,
S. Nagata,
H. Hengartner, and P. Golstein.
1994.
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity.
Science
265:528-530[Abstract/Free Full Text].
|
| 11.
|
Kagi, D.,
B. Ledermann,
K. Burki,
P. Seiler,
B. Odermatt,
K. J. Olsen,
E. R. Podack,
R. M. Zinkernagel, and H. Hengartner.
1994.
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice.
Nature
369:31-37[Medline].
|
| 12.
|
Kent, S. B. H., and L. E. A. N. Hood.
1985.
A novel approach to automated peptide synthesis based on new insight into solid phase chemistry, p. 217.
In
J. Izumiya (ed.), Peptides chemistry. Protein Research Foundation, Osaka, Japan.
|
| 13.
|
Kojima, H.,
K. Eshima,
H. Takayama, and M. Sitkovsky.
1997.
Leukocyte function-associated antigen-1-dependent lysis of Fas+ (CD95+/Apo-1+) innocent bystanders by antigen-specific CD8+ CTL.
J. Immunol.
159:2728-2734[Abstract].
|
| 14.
|
Kojima, H.,
N. Shinohara,
S. Hanaoka,
Y. Someya-Shiorota,
Y. Takagaki,
H. Ohno,
T. Saitoh,
T. Katayama,
H. Yagita,
K. Okumura,
Y. Shinkai,
F. W. Alt,
A. Matsuzawa,
S. Yonehara, and H. Takayama.
1994.
Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes.
Immunity
1:357-364[Medline].
|
| 15.
|
Lancki, D. W.,
A. Weiss, and F. W. Fitch.
1987.
Requirements for triggering of lysis by cytolytic T lymphocyte clones.
J. Immunol.
138:3646-3653[Abstract].
|
| 16.
|
Langlet, C.,
G. A. Neil, and L. A. Sherman.
1987.
The mechanism of anti-Lyt-2 inhibition of antibody-directed lysis by cytotoxic T lymphocytes.
J. Immunol.
139:3590-3596[Abstract].
|
| 17.
|
Lenardo, M. J.
1991.
Interleukin-2 programs mouse  T lymphocytes for apoptosis.
Nature
353:858-861[Medline].
|
| 18.
|
Ljunggren, H. G., and K. Karre.
1985.
Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism.
J. Exp. Med.
162:1745-1759[Abstract/Free Full Text].
|
| 19.
|
Lowin, B.,
F. Beermann,
A. Schmidt, and J. Tschopp.
1994.
A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity.
Proc. Natl. Acad. Sci. USA
91:11571-11575[Abstract/Free Full Text].
|
| 20.
|
Lowin, B.,
M. Hahne,
C. Mattmann, and J. Tschopp.
1994.
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways.
Nature
370:650-652[Medline].
|
| 21.
|
Lub, M.,
Y. van Kooyk, and C. G. Figdor.
1995.
Ins and outs of LFA-1.
Immunol. Today
16:479-483[Medline].
|
| 22.
|
Nagata, S., and P. Golstein.
1995.
The Fas death factor.
Science
267:1449-1456[Abstract/Free Full Text].
|
| 23.
|
Nakamoto, Y.,
L. G. Guidotti,
V. Pasquetto,
R. D. Schreiber, and F. V. Chisari.
1997.
Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice.
J. Immunol.
158:5692-5697[Abstract].
|
| 24.
|
Ogasawara, J.,
R. Watanabe-Fukunaga,
M. Adachi,
A. Matsuzawa,
T. Kasugai,
Y. Kitamura,
N. Itoh,
T. Suda, and S. Nagata.
1993.
Lethal effect of the anti-Fas antibody in mice.
Nature
364:806-809[Medline].
|
| 25.
|
Ossina, N. K.,
A. Cannas,
V. C. Powers,
P. A. Fitzpatrick,
J. D. Knight,
J. R. Gilbert,
E. M. Shekhtman,
L. D. Tomei,
S. R. Umansky, and M. C. Kiefer.
1997.
Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression.
J. Biol. Chem.
272:16351-16357[Abstract/Free Full Text].
|
| 26.
|
Podack, E. R.,
H. Hengartner, and M. G. Lichtenheld.
1991.
A central role of perforin in cytolysis?
Annu. Rev. Immunol.
9:129-157[Medline].
|
| 27.
|
Rathmell, J. C.,
M. P. Cooke,
W. Y. Ho,
J. Grein,
S. E. Townsend,
M. M. Davis, and C. C. Goodnow.
1995.
CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells.
Nature
376:181-184[Medline].
|
| 28.
|
Rathmell, J. C.,
S. E. Townsend,
J. C. Xu,
R. A. Flavell, and C. C. Goodnow.
1996.
Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor.
Cell
87:319-329[Medline].
|
| 29.
|
Rose, N. R.
1996.
Myocarditis from infection to autoimmunity.
Immunologist
4:67.
|
| 30.
|
Rouvier, E.,
M.-F. Luciani, and P. Golstein.
1993.
Fas involvement in Ca2+-independent T cell-mediated cytotoxicity.
J. Exp. Med.
177:195-200[Abstract/Free Full Text].
|
| 31.
|
Sieg, S.,
Y. Huang, and D. Kaplan.
1997.
Viral regulation of CD95 expression and apoptosis in T lymphocytes.
J. Immunol.
159:1192-1199[Abstract].
|
| 32.
|
Sligh, J. E., Jr.,
C. M. Ballantyne,
S. S. Rich,
H. K. Hawkins,
C. W. Smith,
A. Bradley, and A. L. Beaudet.
1993.
Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1.
Proc. Natl. Acad. Sci. USA
90:8529-8533[Abstract/Free Full Text].
|
| 33.
|
Smith, C. A.,
T. Farrah, and R. G. Goodwin.
1994.
The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death.
Cell
76:959-962[Medline].
|
| 34.
|
Smyth, M. J.
1997.
Fas ligand-mediated bystander lysis of syngeneic cells in response to an allogeneic stimulus.
J. Immunol.
158:5765-5772[Abstract].
|
| 35.
|
Smyth, M. J., and J. A. Trapani.
1995.
Granzymes: exogenous proteinases that induce target cell apoptosis.
Immunol. Today
16:202-206[Medline].
|
| 36.
|
Smyth, M. J.,
V. R. Sutton,
M. H. Kershaw, and J. A. Trapani.
1996.
Xenospecific cytotoxic T lymphocytes use perforin- and Fas-mediated lytic pathways.
Transplantation
62:1529-1532[Medline].
|
| 37.
|
van den Broek, M. E.,
D. Kagi,
F. Ossendorp,
R. Toes,
S. Vamvakas,
W. K. Lutz,
C. J. Melief,
R. M. Zinkernagel, and H. Hengartner.
1996.
Decreased tumor surveillance in perforin-deficient mice.
J. Exp. Med.
184:1781-1790[Abstract/Free Full Text].
|
| 38.
|
Vignaux, F.,
E. Vivier,
B. Malissen,
V. Depraetere,
S. Nagata, and P. Golstein.
1995.
TCR/CD3 coupling to Fas-based cytotoxicity.
J. Exp. Med.
181:781-786[Abstract/Free Full Text].
|
| 39.
|
Walsh, C. M.,
M. Matloubian,
C.-C. Liu,
R. Ueda,
C. Kurahara,
J. Christensen,
M. T. F. Huang,
J. D.-E. Young,
R. Ahmed, and W. R. Clark.
1994.
Immune function in mice lacking the perforin gene.
Proc. Natl. Acad. Sci. USA
91:10854-10858[Abstract/Free Full Text].
|
| 40.
|
Wang, J., and M. J. Lenardo.
1997.
Essential lymphocyte function associated 1 (LFA-1): intercellular adhesion molecule interactions for T cell-mediated B cell apoptosis by Fas/APO-1/CD95.
J. Exp. Med.
186:1171-1176[Abstract/Free Full Text].
|
| 41.
|
Wang, R.,
A. M. Rogers,
T. L. Ratliff, and J. H. Russell.
1996.
CD95-dependent lysis caused by CD4+ T helper 1 effectors.
J. Immunol.
157:2961-2968[Abstract].
|
| 42.
|
Zheng, L.,
G. Fisher,
R. E. Miller,
J. Peschon,
D. H. Lynch, and M. J. Lenardo.
1995.
Induction of apoptosis in mature T cells by tumour necrosis factor.
Nature
377:348-351[Medline].
|
| 43.
|
Zhu, X.,
M. Tommasino,
K. Vousden,
E. Sadovnikava,
R. Rappuoli,
L. Crawford,
M. Kast,
C. J. Melief,
P. C. Beverley, and H. J. Stauss.
1995.
Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice.
Scand. J. Immunol.
42:557-563[Medline].
|
J Virol, July 1998, p. 5948-5954, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Inaba, H., Geiger, T. L.
(2006). Defective cell cycle induction by IL-2 in naive T-cells antigen stimulated in the presence of refractory T-lymphocytes. Int Immunol
18: 1043-1054
[Abstract]
[Full Text]
-
Gremion, C., Grabscheid, B., Wolk, B., Moradpour, D., Reichen, J., Pichler, W., Cerny, A.
(2004). Cytotoxic T Lymphocytes Derived from Patients with Chronic Hepatitis C Virus Infection Kill Bystander Cells via Fas-FasL Interaction. J. Virol.
78: 2152-2157
[Abstract]
[Full Text]
-
Topham, D. J., Cardin, R. C., Christensen, J. P., Brooks, J. W., Belz, G. T., Doherty, P. C.
(2001). Perforin and Fas in murine gammaherpesvirus-specific CD8+ T cell control and morbidity. J. Gen. Virol.
82: 1971-1981
[Abstract]
[Full Text]
-
Cretney, E., Degli-Esposti, M. A., Densley, E. H., Farrell, H. E., Davis-Poynter, N. J., Smyth, M. J.
(1999). M144, a Murine Cytomegalovirus (Mcmv)-Encoded Major Histocompatibility Complex Class I Homologue, Confers Tumor Resistance to Natural Killer Cell-Mediated Rejection. JEM
190: 435-444
[Abstract]
[Full Text]
-
Brochu, S., Rioux-Masse, B., Roy, J., Roy, D.-C., Perreault, C.
(1999). Massive Activation-Induced Cell Death of Alloreactive T Cells With Apoptosis of Bystander Postthymic T Cells Prevents Immune Reconstitution in Mice With Graft-Versus-Host Disease. Blood
94: 390-400
[Abstract]
[Full Text]
-
Liu, A. N., Mohammed, A. Z., Rice, W. R., Fiedeldey, D. T., Liebermann, J. S., Whitsett, J. A., Braciale, T. J., Enelow, R. I.
(1999). Perforin-Independent CD8+ T-Cell-Mediated Cytotoxicity of Alveolar Epithelial Cells Is Preferentially Mediated by Tumor Necrosis Factor-alpha . Relative Insensitivity to Fas Ligand. Am. J. Respir. Cell Mol. Bio.
20: 849-858
[Abstract]
[Full Text]
-
Johnstone, R. W., Cretney, E., Smyth, M. J.
(1999). P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death. Blood
93: 1075-1085
[Abstract]
[Full Text]